For Merck, 2012 was a record year. More licensing deals than ever before were executed across multiple therapeu¬tic areas and multiple clinical stages.
Collaborating with academic researchers worldwide is a central part of Merck's mission to turn breakthrough science into new medicines that improve lives.
Darryle Schoepp, senior vice president and franchise head for neuroscience and ophthalmology, talks about Merck's pipeline, commitment and partnerships.
Merck has announced the appointment of Roger Pomerantz, M.D., F.A.C.P., to senior vice president and head, Worldwide Licensing and Knowledge Management at Merck.
Merck has a long tradition of successful partnerships. We recognize that the greatest achievements are not reached alone. They are the result of teamwork.
Biotechs have given Merck top marks in a recent survey on partnering, including "responsiveness" and "allowing partners to develop and prosper".
In June 2009, AstraZeneca and Merck began an agreement to conduct joint phase 1 clinical trials for treating solid cancer tumors. In November 2010, this pioneering collaboration won a Scrip Award for Best Partnership Alliance.
Dr. Greg Wiederrecht, head of Merck's External Scientific Affairs team, reflects on the Merck/Celera collaboration that turned a scientific discovery into a new drug candidate for treating osteoporosis.
For Brian Daly, head of Alliance Management for Merck's Worldwide Licensing organization, the real work for his team begins after the alliance contact is signed.
At Merck, flexibility, innovation and creativity are at the heart of the way we work with partners around the world.
Our Licensing team works with partners to advance their science through drug discovery and development collaborations and licensing agreements that are mutually beneficial.
Our Commercial Partnerships team pursues business opportunities with partners to jointly deliver their products and ours to the marketplace.